Polym Int 2007, 56:1272–1280.CrossRef 30. Mei L, Zhang Y, Zheng Y, Tian G, Song C, Yang D, Chen H, Sun
H, Tian Y, Liu K, Apoptosis inhibitor Li Z, Huang L: A novel paclitaxel-loaded poly (ε-caprolactone)/pluronic F68 nanoparticle overcoming multidrug resistance for breast IPI-549 purchase cancer treatment. Nanoscale Res Lett 2009, 4:1530–1539.CrossRef 31. Mei L, Sun H, Jin X, Zhu D, Sun R, Zhang M, Song C: Modified paclitaxel-loaded nanoparticles for inhibition of hyperplasia in a rabbit arterial balloon injury model. Pharm Res 2007,24(5):955–962.CrossRef 32. Ma Y, Huang LQ, Song CX, Zeng XW, Liu G, Mei L: Nanoparticle formulation of poly(ε-caprolactone-co-lactide)-d-α-tocopheryl polyethylene glycol 1000 succinate random copolymer for cervical cancer treatment. Polymer 2010, 51:5952–5959.CrossRef 33. Barr WH, Riegelman S: Intestinal drug absorption and metabolism. I. Comparison of methods and MK-1775 ic50 models to study physiological factors of in vitro and in vivo intestinal absorption. J Pharm Sci 1970,59(2):154–163.CrossRef
34. Hosseinzadeh H, Atyabi F, Dinarvand R, Ostad SN: Chitosan–pluronic nanoparticles as oral delivery of anticancer gemcitabine: preparation and in vitro study. Int J Nanomedicine 2012, 7:1851–1863.CrossRef 35. Florence AT: Nanoparticle uptake by the oral route: fulfilling its potential? Drug Discov Today 2005, 2:75–81.CrossRef 36. Norris DA, Puri N, Sinko PJ: The effect of physical barriers and properties Reverse transcriptase on the oral absorption of particulates. Adv Drug Deliv Rev 1998,34(2–3):135–154.CrossRef 37. Hariharan S, Bhardwaj V, Bala I, Sitterberg J, Bakowsky U, Ravi Kumar MN: Design
of estradiol loaded PLGA nanoparticulate formulations: a potential oral delivery system for hormone therapy. Pharm Res 2006, 23:184–196.CrossRef 38. Artursson P, Palm K, Luthman K: Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev 2001, 46:27–43.CrossRef 39. Nabholtz JM, Tonkin K, Smylie M, Au HJ, Lindsay MA, Mackey J: Chemotherapy of lung cancer: are the taxanes going to change the natural history of lung cancer? Expert Opin Pharmacother 2000,1(2):187–206.CrossRef 40. Yan F, Zhang C, Zheng Y, Mei L, Tang L, Song C, Sun H, Huang L: The effect of poloxamer 188 on nanoparticle morphology, size, cancer cell uptake, and cytotoxicity. Nanomedicine 2010,6(1):170–178.CrossRef 41. Leroueil PR, Hong S, Mecke A, Baker JR Jr, Orr BG, Banaszak Holl MM: Nanoparticle interaction with biological membranes: does nanotechnology present a Janus face? Acc Chem Res 2007, 40:335–342.CrossRef 42. Song C, Labhasetwar V, Cui X, Underwood T, Levy RJ: Arterial uptake of biodegradable nanoparticles for intravascular local drug delivery: results with an acute dog model. J Control Release 1998,54(2):201–211.CrossRef 43.